Medical Cannabis in Canada: Evidence for Neuropathic Pain and Practical Barriers to Use | Research

The takeaway

A review of medical cannabis in Canada found strong evidence for neuropathic pain relief with a dose-dependent relationship, while identifying barriers including cost, addiction concerns, stigma, and physician reluctance.

Read this if you are interested in medical cannabis for pain and the practical challenges of accessing it within a healthcare system.

Dose-dependent neuropathic pain relief demonstrated in multiple RCTs

What the researchers found

This review addressed the rapidly evolving Canadian medical cannabis landscape from both clinical and practical perspectives. Several randomized controlled trials demonstrated a significant, dose-dependent relationship between THC and neuropathic pain relief.

However, significant barriers existed on both sides. From the patient perspective: cost (not covered by insurance), addiction concerns, social stigma, and lack of understanding about safe administration. From the physician perspective: questions about credibility, concern about criminality, gaps in clinical evidence, worry about patient addiction, and restrictive policies from medical governing bodies.

The review included case studies demonstrating medical marijuana use for neuropathic low-back pain, fibromyalgia, and multiple sclerosis. While preclinical data supported potential benefits for osteoarthritis, rheumatoid arthritis, fibromyalgia, and cancer pain, larger clinical trials were needed.

Why it matters

Canada was among the first countries to establish a comprehensive medical cannabis framework. The barriers identified in this review are universal challenges that any jurisdiction must address when implementing medical cannabis programs.

The numbers in context

Multiple RCTs showed dose-dependent neuropathic pain relief with THC. Key barriers identified on both patient and physician sides. Case studies covered neuropathic low-back pain, fibromyalgia, and MS pain. Preclinical support for OA, RA, fibromyalgia, and cancer pain applications.

How the study worked

Narrative review of clinical evidence and practical considerations for medical cannabis in the Canadian healthcare system, including case studies of patients with neuropathic pain conditions.

What this study cannot tell us

Narrative review without systematic methodology. Case studies provide anecdotal rather than statistical evidence. Canadian-specific regulatory context may limit generalizability. Published before significant changes in Canadian cannabis law (2018 legalization).

How to read the evidence

Narrative review with case studies. Provides practical clinical context but limited by non-systematic methodology.

When this study was published

Published in 2016, before Canada's full cannabis legalization in 2018. The medical cannabis landscape has changed significantly.

The bigger picture

This review captured a moment when medical cannabis was legal but practical access remained limited by systemic barriers. The tension between growing evidence and persistent institutional resistance reflects a broader challenge in integrating cannabinoid therapies into conventional medicine.

Questions still open

How has full legalization in 2018 affected medical cannabis access and physician attitudes in Canada? Have the identified barriers been resolved? Would standardized physician training improve medical cannabis prescribing?

Common questions

Does medical cannabis work for nerve pain?

Multiple randomized controlled trials have shown a significant, dose-dependent relationship between THC and neuropathic pain relief, making it one of the better-supported medical cannabis applications.

What are the main barriers to using medical cannabis?

Key barriers include cost (often not covered by insurance), concerns about addiction, social stigma, lack of safe-use education for patients, and physician reluctance due to evidence gaps and professional concerns.

Read the original research

Medical cannabis - the Canadian perspective.

Journal of pain research, 9, 735-744

View on PubMed ↗

Citation

Ko, Gordon D; Bober, Sara L; Mindra, Sean; Moreau, Jason M. (2016). Medical cannabis - the Canadian perspective.. Journal of pain research, 9, 735-744.